에 대한 최신 뉴스 Alcon (NYSE:ALC) 주식

Alcon

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

FLNT

PANW

화요일 오전 (현지 시간 기준) 미국 주식 선물이 약간 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 로우스(NYSE:LOW)가 개장 전 240억 1천만 달러의 매출과 주당 3.99달러의 분기 이익을 보고할 것으로 예상하고 있다. 벤징가 프로(Benzinga Pro)의 데이터에 따르면 로우스의 주가는 시간외 거래에서 0.2% 하락한 242.70달러를 기록했다.

화요일 주목해야 할 주식: 로우스, 알콘, 팔로알토 네트웍스 그리고 2종목

Equities

Large Cap

News

Movers

CRBG

DELL

MNDY

MSTR

ONON

PODD

SMCI

지난주 이들 대형주들은 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 마이크로스트레티지(NASDAQ:MSTR)의 주가가 비트코인 가격 상승 이후 30.10% 상승했다. 먼데이닷컴(NASDAQ:MNDY)의 주가는 예상보다 나은 1분기 재무 결과와 예상보다 높은 2분기 FY24 매출 지침에 따라 주가는 25.97% 상승했다. 몇몇 분석가들은 이 회사의 목표 가격을 높였다.

지난주 최고의 성과를 보인 마이크로스트레티지를 포함한 10개의 대형주 (5월 12일-18일)

Alcon Inc

Alternus Clean Energy, Inc. - Class A Common Stock

Alternus Clean Energy Inc

ALLIANCE INTL EDCATN LSNG by ALLIANCE INTL EDUCATION LEASING HLDGS LTD.

Alliance International Education Leasing Holdings Ltd

ALTECH CORP KANAGAWA by ALTECH CORP KANAGAWA

Altech Corp

ATLANTIC CNTRL ENTRPR LTD by Atlantic Central Enterprise Ltd.

Atlantic Central Enterprises Ltd

Alico Inc

ALCHIP TECHNOLOGS LTD TWD by ALCHIP TECHNOLOGIES LIMITED

Alchip Technologies Ltd

Alpha Copper Corp Ordinary Shares

Alpha Copper Corp

Alchemix - United States dollar

Alchemy Investments Acquisition Corp 1 - Class A Ordinary Shares

Alchemy Investments Acquisition Corp 1

Alchemy Investments Acquisition Corp 1 - Units

Alchemy Investments Acquisition Corp 1 - Warrants

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and lowers the price target from $107 to $103.

Price Target

Analyst Ratings

Needham Maintains Buy on Alcon, Lowers Price Target to $103

Needham analyst David Saxon reiterates Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and maintains $107 price target.

Reiteration

Needham Reiterates Buy on Alcon, Maintains $107 Price Target

WIIM

Alcon shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results, issued FY24 core diluted EPS guidance below estimates, and cut its FY24 net sales guidance.

2024 outlook
The Company updated its 2024 outlook as per the table below.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">2024 outlook4</td>
<td colspan="1" rowspan="1">as of February</td>
<td colspan="1" rowspan="1">as of May</td>
<td colspan="1" rowspan="1">as of August</td>
<td colspan="1" rowspan="1">as of November</td>
<td colspan="1" rowspan="1">Comments</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales (USD)</td>
<td colspan="1" rowspan="1">$9.9 to $10.1 billion</td>
<td colspan="1" rowspan="1">$9.9 to $10.1 billion</td>
<td colspan="1" rowspan="1">$9.9 to $10.1 billion</td>
<td colspan="1" rowspan="1">$9.8 to $9.9 billion</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Change vs. prior year (cc)1
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">+6% to +8%</td>
<td colspan="1" rowspan="1">+7% to +9%</td>
<td colspan="1" rowspan="1">+7% to +9%</td>
<td colspan="1" rowspan="1">+6% to +7%</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Core operating margin2
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">20.5% to 21.5%</td>
<td colspan="1" rowspan="1">20.5% to 21.5%</td>
<td colspan="1" rowspan="1">20.5% to 21.5%</td>
<td colspan="1" rowspan="1">20.5% to 21%</td>
<td colspan="1" rowspan="1">Tightened range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Interest expense and
Other financial income &amp; expense
</td>
<td colspan="1" rowspan="1">$190 to $210 million</td>
<td colspan="1" rowspan="1">$180 to $200 million</td>
<td colspan="1" rowspan="1">$160 to $180 million</td>
<td colspan="1" rowspan="1">$155 to $165 million</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Core effective tax rate5
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">~20%</td>
<td colspan="1" rowspan="1">~20%</td>
<td colspan="1" rowspan="1">~20%</td>
<td colspan="1" rowspan="1">~19%</td>
<td colspan="1" rowspan="1">Updated</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Core diluted EPS2
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">$3.00 to $3.10</td>
<td colspan="1" rowspan="1">$3.00 to $3.10</td>
<td colspan="1" rowspan="1">$3.00 to $3.10</td>
<td colspan="1" rowspan="1">$3.00 to $3.05</td>
<td colspan="1" rowspan="1">Tightened range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Change vs. prior year (cc)1
(non-IFRS measure)
</td>
<td colspan="1" rowspan="1">+13% to +16%</td>
<td colspan="1" rowspan="1">+15% to +18%</td>
<td colspan="1" rowspan="1">+15% to +18%</td>
<td colspan="1" rowspan="1">+15% to +17%</td>
<td colspan="1" rowspan="1">Tightened range</td>
</tr>
</tbody>
</table>
</figure>
This outlook assumes the following:
<ul>
<li>Aggregated markets grow in line with recent quarters;</li>
<li>Exchange rates as of the end of October 2024 prevail through year-end;</li>
<li>Approximately 498 million weighted-averaged diluted shares.</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">4.</td>
<td colspan="1" rowspan="1">The forward-looking guidance included in this press release cannot be reconciled to the comparable IFRS measures without unreasonable effort, because we are not able to predict with reasonable certainty the ultimate amount or nature of exceptional items in the fiscal year. Refer to the 'Footnotes' section for additional information.</td>
</tr>
<tr>
<td colspan="1" rowspan="1">5.</td>
<td colspan="1" rowspan="1">Core effective tax rate, a non-IFRS measure, is the applicable annual tax rate on core taxable income. Refer to the 'Footnotes' section for additional information.</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Guidance

Alcon Updates FY24 Core Diluted EPS From $3.00-$3.10 To $3.00-$3.05 Vs $3.06 Est.; Net Sales From $9.9B-$10.1B To $9.8B-$9.9B Vs $9.93B Est.

Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.74 by 9.46 percent. This is a 22.73 percent increase over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $2.43 billion which missed the analyst consensus estimate of $2.46 billion by 1.10 percent. This is a 5.64 percent increase over sales of $2.30 billion the same period last year.

Earnings

Alcon Q3 Adj EPS $0.81 Beats $0.74 Estimate, Sales $2.43B Miss $2.46B Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Keybanc analyst Brett Fishbin maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Overweight and raises the price target from $103 to $107.

Keybanc Maintains Overweight on Alcon, Raises Price Target to $107

BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $104 to $106.

BTIG Maintains Buy on Alcon, Raises Price Target to $106

Redburn Atlantic analyst Issie Kirby upgrades Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) from Sell to Neutral.

Upgrades

Redburn Atlantic Upgrades Alcon to Neutral

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Needham raised the price target for Docebo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) from $45 to $50. Needham analyst Ryan MacDonald maintained a Buy rating. Docebo shares fell 0.9% to close at $41.29 on Wednesday. <a href="https://www.benzinga.com/quote/DCBO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Ascendiant Capital increased the price target for RenovoRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) from $8 to $8.25.. Ascendiant Capital analyst Edward Woo maintained a Buy rating. RenovoRx shares rose 0.1% to close at $1.05 on Wednesday. <a href="https://www.benzinga.com/quote/rnxt/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. raised Instil Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) price target from $25 to $40. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Instil Bio shares gained 20.6% to close at $29.65 on Wednesday. <a href="https://www.benzinga.com/quote/til/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $580 to $535. Baird analyst David Tarantino maintained an Outperform rating. Domino&#8217;s shares fell 2.1% to close at $407.97 on Wednesday. <a href="https://www.benzinga.com/quote/dpz/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler raised the price target for Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) from $75 to $85. Piper Sandler analyst David Westenberg maintained an Overweight rating. Exact Sciences shares gained 9.8% to close at $64.12 on Wednesday. <a href="https://www.benzinga.com/quote/exas/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities boosted Aramark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARMK#NYSE">ARMK</a>) price target from $37 to $42. Truist Securities analyst Jasper Bibb maintained a Buy rating. Aramark shares gained 0.5% to close at $37.99 on Wednesday. <a href="https://www.benzinga.com/quote/armk/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley increased TransUnion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) price target from $96 to $103. Morgan Stanley analyst Toni Kaplan maintained an Overweight rating. TransUnion shares rose 0.2% to close at $96.44 on Wednesday. <a href="https://www.benzinga.com/quote/tru/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho cut the price target for Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) from $45 to $38. Mizuho analyst David Bellinger maintained a Neutral rating. Advance Auto Parts shares rose 0.6% to close at $38.77 on Wednesday. <a href="https://www.benzinga.com/quote/aap/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho boosted American Tower Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) price target from $205 to $221. Mizuho analyst Vikram Malhorta maintained a Neutral rating. American Tower shares fell 1.6% to close at $238.97 on Wednesday. <a href="https://www.benzinga.com/quote/amt/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG raised Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) price target from $98 to $104. BTIG analyst Ryan Zimmerman maintained a Buy rating. Alcon shares rose 0.1% to close at $98.22 on Wednesday. <a href="https://www.benzinga.com/quote/dpz/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying EXAS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-1024x517.png" alt="" class="wp-image-544353" style="width:612px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100-768x387.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12075315/image-100.png 1342w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

ARMK

DCBO

EXAS

RNXT

Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday

BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $98 to $104.

BTIG Maintains Buy on Alcon, Raises Price Target to $104

RBC Capital analyst Jack Reynolds-Clark upgrades Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) from Sector Perform to Outperform.

RBC Capital Upgrades Alcon to Outperform

Alcon Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) reported mixed second-quarter results, <a href="https://www.benzinga.com/quote/ALC/earnings">after the closing bell on Tuesday.</a>
Alcon reported quarterly earnings of 74 cents per share which beat the analyst consensus estimate of 73 cents per share. The company reported quarterly sales of $2.48 billion which missed the analyst consensus estimate of $2.52 billion.
&#8220;We are pleased with our solid second-quarter results, which were driven by robust demand for our innovative products, our balanced geographic footprint and strong execution by our team. These factors contributed to another quarter of sales and earnings growth and robust cash generation,&#8221; said David J. Endicott, Alcon&#8217;s Chief Executive Officer. &#8220;As we look to the second half of the year, our focus will be on preparing for product launches that will position us well for our next phase of growth in 2025 and beyond.&#8221;
Alcon said it sees FY24 earnings of $3.00 to $3.10 per share on revenue of $9.9 billion to $10.1 billion.
Alcon shares gained 0.9% to trade at $95.50 on Thursday.
These analysts made changes to their price targets on Alcon following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e4d0a4aece4e600011f1fdc/david-saxon">Needham analyst David Saxon</a> maintained Alcon with a Buy and raised the price target from $101 to $107.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586bc4bd351b9b0001ab7364/jeff-johnson">Baird analyst Jeff Johnson</a> maintained the stock with an Outperform and raised the price target from $104 to $110.</li>
<li>BTIG analyst Ryan Zimmerman maintained Alcon with a Buy, while increasing the price target from $96 to $98.</li>
<li>Oppenheimer analyst <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e4d0a4aece4e600011f1fdc/david-saxon">Steven Lichtman</a> maintained the stock with an Outperform and raised the price target from $103 to $110.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584eee82ee7bf60001abdc10/larry-biegelsen">Wells Fargo analyst Larry Biegelsen</a> maintained Alcon with an Overweight rating, while raising the price target from $94 to $105.</li>
</ul>
Considering buying ALC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="524" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200-1024x524.png" alt="" class="wp-image-509074" style="width:573px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200-1024x524.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200-768x393.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/22120010/image-200.png 1302w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Alcon Analysts Increase Their Forecasts After Q2 Results

Wells Fargo analyst Larry Biegelsen maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Overweight and raises the price target from $94 to $105.

Wells Fargo Maintains Overweight on Alcon, Raises Price Target to $105

Oppenheimer analyst Steven Lichtman maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $103 to $110.

Oppenheimer Maintains Outperform on Alcon, Raises Price Target to $110

BTIG analyst Ryan Zimmerman maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $96 to $98.

BTIG Maintains Buy on Alcon, Raises Price Target to $98

Baird analyst Jeff Johnson maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Outperform and raises the price target from $104 to $110.

Baird Maintains Outperform on Alcon, Raises Price Target to $110

Needham analyst David Saxon maintains Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and raises the price target from $101 to $107.

Needham Maintains Buy on Alcon, Raises Price Target to $107

Alcon, Inc.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alc#NYSE">ALC</a>) delivered core earnings per share of 74 cents in the second quarter of 2024, up 7.2% from the year-ago quarter&#39;s figure (up 15% at the constant exchange rate or CER). The figure came in line with the Zacks Consensus Estimate.
Alcon reports &lsquo;core&#39; results based on non-IFRS (International Financial Reporting Standards) measures. In the second quarter, the company&#39;s diluted EPS was 45 cents, up 32.4% year over year.
<h3>Revenues in Detail</h3>
Alcon&#39;s net sales to third parties in the second quarter were $2.48 billion, which missed the Zacks Consensus Estimate by 1.4%. However, the top line increased by 3.3% from the year-ago quarter&#39;s levels (up 6% at CER).
<h3>Quarter in Detail</h3>
Alcon reports operations through two segments &mdash; Surgical (comprising Implantables, Consumables and Equipment/Other) and Vision Care (comprising Contact Lenses and Ocular Health).
Surgical
In the second quarter of 2024, Surgical sales amounted to $1.42 billion, up 3% year over year and 6% at CER. Our model projected the segment&#39;s growth to be 3.5% versus the prior year.
Within this, net sales in Implantables increased 6%, led by the demand for advanced technology intraocular lenses in international markets. Our model projected 3.1% year-over-year growth.
Consumables increased 3%, mainly driven by cataract and vitreoretinal consumables, particularly in international markets, and price increases. Our model&#39;s projection was an increase of 4.9%.
<div class="chart_embed">
<h3>Alcon Price, Consensus and EPS Surprise</h3>
<img alt="Alcon Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/dc/1724230877.png" style="height:265px; width:576px" title="" />
Alcon price-consensus-eps-surprise-chart | Alcon Quote
</div>
Equipment/Other was down 3% from the prior-year quarter&#39;s levels. Our model forecast stood at 0.1% growth.
Vision Care
The segment reported total sales of $1.11 billion, up 7% year over year on a reported basis and 10% at CER. Our model&#39;s projection was 6.7% growth.
Net sales of Contact Lenses increased 9% year over year, driven by product innovation, including toric multifocal modalities and price increases. This surpassed our model&#39;s projected growth of 8% year over year.
Ocular Health sales increased 5% year over year, primarily driven by the portfolio of eye drops, including continued strength from the Systane family of artificial tears. Our model forecast was 4.9%.
<h3>Margins</h3>
The cost of net sales in the second quarter was $1.12 billion, up 5.9% year over year. The core gross profit rose 0.8% to $1.37 billion in the reported quarter. Meanwhile, the core gross margin contracted 123 basis points (bps) to 55.1% in the second quarter of 2024.
SG&amp;A expenses increased 0.6% year over year, while R&amp;D expenses rose 1.4% year over year. The core operating margin fell 26 bps in the second quarter to 12.7%.
<h3>Financial Position</h3>
Alcon exited the second quarter of 2024 with cash and cash equivalents of $1.37 billion compared with $1.14 billion at the end of the first quarter.
The cumulative net cash flow from operating activities at the end of the second quarter was $871 million compared with $410 million in the year-ago period. Free cash flow totaled $667 million at the end of the second quarter of 2024 compared with $189 million in the comparable 2023 months.
<h3>2024 Outlook</h3>
Alcon reiterated its financial outlook for 2024.
The company anticipates 2024 net sales in the range of $9.90-$10.10 billion (unchanged), indicating growth of 7%-9% at CER from 2023. The Zacks Consensus Estimate for ALC&#39;s revenues is pegged at $9.94 billion.
Core EPS for the full year is expected in the range of $3.00-$3.10 (same as earlier). This suggests growth of 15%-18%% at CER from the 2023 levels. The Zacks Consensus Estimate for Alcon&#39;s 2024 earnings is currently pegged at $3.05 per share.
<h3>Our Take</h3>
Alcon closed the second quarter of 2024 with in-line earnings, while revenues missed estimates. On a positive note, the top line improved on a year-over-year basis. The performance was driven by robust demand for the company&#39;s innovative products, balanced geographic footprint and strong execution by the team. Growth in the Vision Care segment underscores the strength of contact lenses.
In June 2024, Alcon&#39;s innovations from the highly anticipated UNITY portfolio, Vitreoretinal Cataract System and Cataract System, secured the FDA&#39;s 510(k) clearance. In the second half of the year, Alcon is preparing for product launches that are set to drive its next phase of growth in 2025 and beyond.
Meanwhile, the contraction of both margins in the quarter is discouraging.
<h3>Zacks Rank and Other Key Picks</h3>
Alcon currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Intuitive Surgical, DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) and Veracyte (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcyt#NASDAQ">VCYT</a>).
Intuitive Surgicalreported a third-quarter 2024 adjusted EPS of $1.78, which beat the Zacks Consensus Estimate by 16.3%. Revenues of $2.01 billion topped the consensus estimate by 2%. ISRG currently sports a Zacks Rank #1 (Strong Buy).
Intuitive Surgical has an estimated long-term earnings growth rate of 16.8% in 2024 compared with the industry&#39;s 11.8%. The company&#39;s earnings surpassed estimates in each of the trailing four quarters, the average being 8.97%.
DaVita, sporting a Zacks Rank #1, reported second-quarter 2024 adjusted earnings of $2.59, which surpassed the Zacks Consensus Estimate by 4.9%. Revenues of $3.19 billion topped the Zacks Consensus Estimate by 0.7%.&nbsp;
DVA has an estimated long-term earnings growth rate of 17.5% compared with the industry&#39;s 12.4%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 24.2%.
Veracyte, sporting a Zacks Rank #1, reported second-quarter diluted earnings of 30 cents per share compared with the Zacks Consensus Estimate of a loss of 3 cents. Revenues of $114.4 million exceeded the Zacks Consensus Estimate by 14%.
VCYT has an estimated 2024 earnings growth rate of 112.8% compared with the industry&#39;s 11.8%. The company surpassed earnings estimates in each of the trailing four quarters, the average being 328.4%.
<a href="https://www.zacks.com/stock/news/2324779/alcon-alc-q2-earnings-meet-estimates-revenues-increase-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2324779">To read this article on Zacks.com click here.</a>

Earnings Beats

Mid Cap

VCYT

Alcon Q2 Earnings Meet Estimates, Revenues Increase Y/Y

Needham analyst David Saxon reiterates Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and maintains $101 price target.

Needham Reiterates Buy on Alcon, Maintains $101 Price Target

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Alcon (NYSE:<a href="https://investorplace.com/stock-quotes/alc-stock-quote/">ALC</a>) just reported results for the second quarter of 2024.<ul><li>Alcon reported earnings per share of 74 cents. This was above the analyst estimate for EPS of 73 cents.</li><li>The company reported revenue of $2.48 billion.</li><li>This was 1.51% worse than the analyst estimate for revenue of $2.52 billion.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/alc-stock-earnings-alcon-for-q2-of-2024/">ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alcon (ALC – Research Report), Innate Pharma SA (I...

Analysts Conflicted on These Healthcare Names: Alcon (ALC), Innate Pharma SA (OtherIPHYF) and scPharmaceuticals (SCPH)

Meeting to be held in New York on November 20 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

Alcon management to meet with BTIG

JPMorgan analyst David Adlington lowered the firm's price target on Alcon (ALC) to CHF 79.60 from CHF 84.30 and keeps an Overweight rating on the s...

Alcon price target lowered to CHF 79.60 from CHF 84.30 at JPMorgan

Deutsche Bank lowered the firm's price target on Alcon (ALC) to CHF 82 from CHF 85 and keeps a Buy rating on the shares. Published first on TheFly ...

Alcon price target lowered to CHF 82 from CHF 85 at Deutsche Bank

Franklin International Growth Fund Q3 2024 Commentary

3 'Buy' stocks and 2 'Hold' stocks according to Oppenheimer

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Haemonetics (HAE – Research Report) and Alcon (ALC –...

Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), Alcon (ALC)

In a report released on December 3, Patrick Wood from Morgan Stanley maintained a Hold rating on Alcon (ALC – Research Report), with a price target...

Morgan Stanley Reaffirms Their Hold Rating on Alcon (ALC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (FATE – Research Report), Veeva Systems (VEEV –...

Comments

Alcon

뉴스

에 대한 최신 뉴스 Alcon (NYSE:ALC) 주식

화요일, 8월 20, 2024

월요일, 5월 20, 2024

뉴스

파트너 / 기고자

벤징가 글로벌